Key result
The DeLiT Trial is a study protocol for a factorial randomized trial evaluating the effects of dexamethasone, tight glucose control, and light anesthesia on perioperative morbidity and mortality.
Why the study?
Do dexamethasone, tight glucose control, and light anesthesia reduce major postoperative morbidity and mortality in patients undergoing major non-cardiac surgery?
RCT (n=970)
Partially blinded
Factorial
No
Do dexamethasone, tight glucose control, and light anesthesia reduce major postoperative morbidity and mortality in patients undergoing major non-cardiac surgery?
The DeLiT trial is designed to evaluate whether a combination of dexamethasone, tight glucose control, and light anesthesia can reduce perioperative inflammation and morbidity in major non-cardiac surgery.
Answers are grounded in this paper and cite their sources.
Protocol for factorial RCT of dexamethasone, tight glucose control, and light anesthesia; leaves open their effects on major postoperative morbidity until results emerge.
BACKGROUND: The perioperative period is characterized by an intense inflammatory response. Perioperative inflammation promotes postoperative morbidity and increases mortality. Blunting the inflammatory response to surgical trauma might thus improve perioperative outcomes. We are studying three interventions that potentially modulate perioperative inflammation: corticosteroids, tight glucose control, and light anesthesia. METHODS/DESIGN: The DeLiT Trial is a factorial randomized single-center trial of dexamethasone vs placebo, intraoperative tight vs. conventional glucose control, and light vs deep anesthesia in patients undergoing major non-cardiac surgery. Anesthetic depth will be estimated with Bispectral Index (BIS) monitoring (Aspect medical, Newton, MA). The primary outcome is a composite of major postoperative morbidity including myocardial infarction, stroke, sepsis, and 30-day mortality. C-reactive protein, a measure of the inflammatory response, will be evaluated as a secondary outcome. One-year all-cause mortality as well as post-operative delirium will be additional secondary outcomes. We will enroll up to 970 patients which will provide 90% power to detect a 40% reduction in the primary outcome, including interim analyses for efficacy and futility at 25%, 50% and 75% enrollment. DISCUSSION: The DeLiT trial started in February 2007. We expect to reach our second interim analysis point in 2010. This large randomized controlled trial will provide a reliable assessment of the effects of corticosteroids, glucose control, and depth-of-anesthesia on perioperative inflammation and morbidity from major non-cardiac surgery. The factorial design will enable us to simultaneously study the effects of the three interventions in the same population, both individually and in different combinations. Such a design is an economically efficient way to study the three interventions in one clinical trial vs three. TRIAL REGISTRATION: This trial is registered at Clinicaltrials.gov #: NTC00433251.
No takes yet. Share an insight, caveat, or question.
Abdelmalak et al. (2010) conducted an RCT in Major non-cardiac surgery (n=970). Dexamethasone, intensive glucose control, and light anesthesia vs. Placebo, conventional glucose control (180-200 mg/dL), deep anesthesia (BIS 35) was evaluated on Composite of major postoperative morbidity (including myocardial infarction, stroke, sepsis) and 30-day mortality. The DeLiT Trial is a study protocol for a factorial randomized trial evaluating the effects of dexamethasone, tight glucose control, and light anesthesia on perioperative morbidity and mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: